Objective: The pulmonary transfer factor for carbon monoxide (TL,,) has been reported to decline following heart transplantation, but the time course of this decline is not well documented. The aim of this study was to define the longitudinal changes in TL,, after hleart transplantation.
Introduction
Heart failure, the primary indication for heart transplantation is associated with a variety of pulmonary function abnormalities including reduced lung volumes, airway dysfunction and impairment of the pulmonary ' Presented at the 10th Annual Meeting of The European Association for Cardio-thoracic Surgery, Prague, Czech Republic, 6-9 October 1996.
transfer factor for carbon monoxide (TL,,) [17, 24] . Heart transplantation has been shown to restore lung volumes and airway function towards normal [3, 15] . In contrast, TL,, and TL,, per unit alveolar volume (K,-o) have been persistently shown either to deteriorate or remain sub-normal following heart transplantation [6, 7, 9, 11, 14, 18, 19, 21] .
The cause of TL,, decline following heart transplantation is not clear [14] . [3] . Since most of these factors occur during the first year after transplantation [13] , it is important to define the longitudinal changes in TL,, during this period. However, most of TL,, studies in heart transplant patients were retrospective and based on cross-sectional analysis of patients assessed at different intervals following transplantation [7, 9, 11, 18, 19, 21] . To our knowledge, there are only two longitudinal studies on TL,, changes following heart transplantation [6, 14] , and in both the number of patients studied was small.
In the first study, Groen et al. [14] reported lung function changes before and serially after heart transplantation.
In this study, 34 patients were assessed at 1 year, and 27 of them had repeat assessments at 2 years, and of these 21 had a third assessment at 3 years after transplantation.
In the first postoperative year, lung volumes and flow rates (TLC, VC, FEV,) tended to normalise.
In contrast, K,, decreased by a mean of 12% (P < 0.01). In the following 2 years, Kc, tended to improve, but remained below its base-line pre-operative value. In the only longitudinal study during the first year after transplantation, Bussieres et al. [6] , reported lung function changes before transplantation and at 1, 3 and 12 months after transplantation in 14 patients. Before transplantation, TL,, and lung volumes were reduced and despite significant improvement of lung volumes and indices of airway function by 3 months after transplantation, TL,, decreased further soon after transplantation and did not improve afterwards. The findings of this small study suggest that the responsible factor in TL,, decline is present within the first few weeks after heart transplantation.
The aim of this study was prospectively to determine the longitudinal changes in TL,, during the first three years after heart transplantation in 57 patients.
Material and methods

Study population
Between January 1992 and February 1996, 98 patients underwent orthotopic heart transplantation at the Scottish Cardiopulmonary Transplantation Unit. Although pulmonary function measurement was part of routine assessment of heart transplant patients in our centre, the longitudinal nature of the follow-up resulted in a number of patients with incomplete lung function results. This was due to one or more of the following reasons:
Transplantation without referral for pre-transplant pulmonary function assessment. Completion of the follow-up period of the study before recent recipients had full post-transplant assessment. Early post-transplant death. Fifty seven of the 98 heart transplant patients had pre-transplant and at least one post-transplant pulmonary function assessment and of these 37 had at least four assessments following transplantation. All heart transplant patients were suffering from severe chronic heart failure before transplantation (mean left ventricular ejection fraction, LVEF = 13.4%) and they were all stable at the time of assessment. Anti-failure medication consisted of diuretics (all patients), digoxin (26), angiotensin converting enzyme inhibitors (45) and other vasodilators (24). After transplantation, patients followed a standard triple immunosuppressive regimen consisting of prednisolone, cyclosporin and azathioprine and all patients were free of rejection and systemic infection during the time of pulmonary function assessment. Heart transplantation was performed using conventional technique as described by Lower and Shumway and modified by Barnard [2] .
The findings in heart transplant patients were compared with data from 28 (23 males) normal subjects recruited as volunteers from the general population in whom there was no evidence of cardiopulmonary disease. Their mean age was 40.4 years (range, 19-61) , and 16 of them were life-long non-smokers, nine former smokers and three were current smokers.
Protocol
Patients were assessed before transplantation and at 6 weeks, 3, 6 and 12 months following transplantation (early assessment group). Patients who were transplanted before the start of the study, but had pre-transplant results as part of their routine assessment for possible heart transplantation were assessed at 12, 18, 24 and 36 months after transplantation (late assessment group).
Pulmonary function tests
Standard spirometry and lung volumes were measured using a body plethysmograph (PK. Morgan Ltd., Kent, UK). Measured variables included forced vital capacity (FVC), forced expiratory volume in one second (FEV,), FEVJFVC ratio, residual volume (RV), and total lung capacity (TLC). TLco was measured using the single breath method (Transflow; PK. Morgan Ltd., Kent, UK) according to the recommendations by the European Respiratory Society (ERS) [8] . Measured TL,, was corrected for patients' actual haemoglobin using the equation described by Cotes et al. [8] . Quality control and procedures of lung function testing were performed according to formal guidelines established by ERS [8, 20] . Predicted normal values of lung function tests were determined using the European Community for Steel and Coal equations [8, 20] .
Data presentation and analysis
Unless stated otherwise, values are expressed as mean + standard error of the mean (SE). Comparisons between results before and after transplantation were performed using the paired samples Student's t-test and comparisons between heart transplant recipients and normal controls were performed using the independent samples Student's t-test. Mean changes in lung function parameters following heart transplantation were calcu-
Early assessment group Late assessment group (n=32) (n=25) Fig. 1 . Comparison between changes in lung function in the 2 sub-groups of heart transplant recipients; the first post -transplant lung measurement was performed at 6 weeks in the early assessment group (n = 32) and at one year in the late assessment group (n = : 25).
lated as the mean of % predicted values after transplantation minus the mean of % predicted before transplantation. A level of P < 0.05 was considered significant. Table 1 shows the clinical characteristics of the 57 heart transplant recipients who had pulmonary function assessment before and at least once after transplantation. Before transplantation they all had severe congestive heart failure (mean left ventricular ejection fraction (LVEF) measured by radionuclide ventriculography was 13.4%). After transplantation, mean LVEF was 47.1%. The pre-transplant mean haemoglobin concentration was 13.4 g.dL -' and decreased to 12.1 g.dL-' after transplantation (P < 0.05). Thirty two of these patients had their first post-transplant assessment at 6 weeks (early assessment group) and the remaining 25 patients at 1 year following transplantation (late assessment group). The mean time between pre-transplant pulmonary function assessment and transplantation was 6.2 months (range; 1 week to 14 months) for the entire group, 7.0 months for the early group and 5.1 months for the late group. For the entire group, mean cyclosporin whole blood level at the time of lung function assessment was 393 (19.8) mcg.L-' with the early assessment group having significantly higher level than the late assessment group. There was no significant difference between the two sub-groups in any of the other listed variables. Table 2 shows lung function in heart transplant patients compared to normal controls. Before transplantation, mean values of FEV,, FVC, FEVJFVC and TLC were slightly reduced. Although above 80% of predicted, they were all significantly lower than the values in normal controls (P < 0.05). The residual volume was slightly elevated, but this was not significantly different from that of normal controls. The greatest impairment, however, was in TLco (haemoglobin-corrected) being 74.3% of predicted compared to 98.6% of predicted in normal subjects (P < 0.001). Although K,, (haemoglobin-corrected) was relatively preserved before transplantation, it was still significantly lower than that of controls (92.6% and 105.3% of predicted respectively, P < 0.05).
Results
Comparisons between pre-and post-transplant results
Clinical characteristics
Effect of heart transplantation
Table 2 also shows that there was no significant change in any of the mean values of lung volumes and expiratory flow rates after transplantation. In contrast, mean TL,, declined significantly following transplantation (from 72.1% to 54.2% of predicted, P < O.OOl), and the decline in K,, was even greater (from 90.1% to 64.0% of predicted, P < 0.001). Although correction for the effect of haemoglobin reduced the magnitude of this decline, it was still significant (mean haemoglobin-corrected TL,, and K,, decreased from 74.3% and 92.6% of predicted to 62.1% and 72.8% of predicted respectively, P < 0.001). Fig. 1 shows that the lack of any significant change in the mean values of lung volumes and expiratory flow rates in the entire group following transplantation was a composite of different changes in the two sub-groups. At 6 weeks following transplantation (early assessment group), there was a reduction in all lung volumes and flow rates, but these changes were not statistically significant. In the late assessment group, there was evidence of improvement in these parameters (FEV,, FVC and TLC increased and RV decreased), but again these changes were not significant. The decline in TL,, and Kc0 were similar in the two sub-groups both before and after correction for the changes in haemoglobin concentration. Fig. 2 displays the {changes in TL,, (haemoglobincorrected) following heart transplantation in individual patients. The upper plot represents the entire group whereas the lower two plots show the individual changes in the early and late assessment groups respectively. TL,, and Kc, declined by more than 10% of predicted in most patients with no difference between the two sub-groups. Table 3 shows that the clinical characteristics of the 37 heart transplant recipients who had both full pulmonary function assessment before and four times after transplantation were similar to the entire group of heart transplant recipients (Table 1 ). The first pulmonary assessment after transplantation was at 6 weeks in 26 patients (early assessment group) and at 12 months in 11 patients (late assessment group). Apart from the difference in the number of patients in each sub-group, there was no significant difference between these tow sub-groups in any of the listed parameters.
Longitudinal changes following heart transplantation
Clinical characteristics
Figs. 3 and 4 show the time course of TL,, and K,, changes in these patients both before and after correc- Table 3 O.A. Al-Rawas et al. /European Journal of Cardio-thoracic Surgery 12 (1997) tion for haemoglobin concentration.
The entire decline in TL,, and Kc, was evident at 6 weeks after transplantation with no further changes afterwards. Although correction for the effect of haemoglobin reduced the magnitude of this decline, it was still significant. In contrast, analysis of the longitudinal changes in lung volumes and flow rates revealed a tendency for FEV,, FVC and TLC to improve with time, but this was not statistically significant. Sub-group analysis showed that FVC and TLC were lower than their pre-transplant values at 6 weeks after transplantation, but both exceeded their pre-transplant baseline in the subsequent interval. There were no consistent changes in RV or FEV,/FVC.
Discussion
The findings of the present study may be summarised as follows: before transplantation there was a mild reduction in lung volumes and expiratory flow rates with greater impairment in TL,,. At 6 weeks after transplantation, there was a further reduction in FEV,, FVC, RV and TLC, but all of these increased in the subsequent measurements to exceed their pre-transplant values at about 1 year after transplantation.
TL,, and Kc, decline was evident at 6 weeks after transplantation with no further changes afterwards. The decline in TLco and K,, occurred in most patients with no significant difference between the early and the late assessment sub-groups.
The changes in lung volumes and expiratory flow rates demonstrated in this study were in agreement with previous reports [6, 9, 14, 15] . The trend and magnitude in TL,, changes during the first year after transplantation in our study are also in agreement with those reported by Bussieres et al. [6] , in 14 heart transplant patients. In the present study, we have confirmed the findings of Bussieres and associates in a larger number of patients and have shown that the early decline in TL,, and Kc, persisted during 3 years of follow-up. In the cross-sectional study of Degre [9], TL,, decline was observed in patients assessed at 1 month after transplantation and the magnitude of decline was similar to those who were assessed as late as 10 years after transplantation.
As the earliest post-transplant assessment in our study was at 6 weeks, it is possible that the TLco decline has occurred well before this time and may be immediately after transplantation (e.g. intra-operatively or during the first few days after transplantation).
In patients undergoing conventional cardiac surgery including coronary surgery, pulmonary dysfunction including TL,, decline has been reported to be maximal within the first few hours after surgery [12, 23] . In addition, measurement of lung function before and one week after percutaneous transvenous mitral commissurotomy demonstrated TL,, decline despite improvement of lung volumes and expiratory flow rates [25] .
Although the magnitude of the observed decline in TL,, in our patients was reduced after correction for haemoglobin, it was still significant. The cause and the underlying mechanisms of the decline in haemoglobincorrected TL,, following heart transplantation have not been determined. H.owever, the isolated decline in TLC0 in the face of improving lung volumes and airway function following transplantation is suggestive of pulmonary vascular dysfunction. An important finding in our study is the identification of the early post-transplant period as the time during which the potential causes of TL,, decline should be sought. These include sternotomy and cardiopulmonary bypass [lo] , early post-operative pulmonary complications [ 131 and the normalisation of pulmonary vascular pressures following transplantation [3,2!i] . In patients undergoing coronary surgery, sternotomy and cardiopulmonary bypass have been shown to be associated with early post-operative decline in TLco, but this usually resolves within 3-6 months after surgery [4, 10] . It is possible that the adverse effects of sternotomy and cardiopulmonary bypass are greater and or .last longer in patients with long
Measured TL, Fig. 4 . Longitudinal changes in &o in 37 heart transplant recipients before and serially after transplantation both before and after correction for haemoglobin concentration. *Significant difference (P < 0.001) between the pre-transplant value and all post-transplant values.
standing heart failure as compared to those undergoing coronary surgery who usually have normal lungs. Alternatively, the normalisation of pulmonary vascular pressures immediately after transplantation may cause TLco decline by reducing the pulmonary capillary blood volume (V,) which is a major determinant of TL,, [1, 5, 22] . In patients with congenital and valvular heart disease, TL,, changes have been shown to be related to the changes in the pulmonary vascular pressures [l] and surgery for these disorders has been reported to be associated with reductions in both pulmonary vascular pressures and TL,, [5, 22] . Before transplantation, the long-standing pulmonary congestion and the associated chronic pulmonary vascular and parenchymal changes would be expected to lead to TL,, impairment by reducing both of its components (the diffusing capacity of the alveolar-capillary membrane, D, and the pulmonary capillary blood volume, V,) [24] . The normalisation of pulmonary haemody-namics and the relief of pulmonary oedema following heart transplantation, would be expected to decrease Vc and increase D,, respectively.
A disproportionate decrease in Vc secondary to the fall in pulmonary vascular pressures, may be an important contributory factor in TL,, decline following heart transplantation. This concept may be tested by the measurement of the TLco components in heart transplant patients. Cyclosporin pulmonary toxicity [7, 14] and cytomegalovirus infection [l l] have also been suggested as possible causes for TL,, decline after heart transplantation. The possible role of all of these factors remains to be determined.
In conclusion, the early and non-progressive nature of TL,, decline suggests an aetiology occurring early after heart transplantation.
The normalisation of pulmonary haemodynamics immediately after transplantation appears to be a plausible cause, but other potential factors need to be evaluated. Studies designed to measure TL,, and its components immediately (within hours to few days) after transplantation by using rebreathing or steady state methods would further clarify the possible causes and mechanisms of TL,, decline after heart transplantation. pulmonary vascular pressures after heart transplantation unmask the effects of pulmonary oedema. and fibrosis of pre-transplant heart failure on the pulmonary transfer factor. Previously, some investigators have implicated cyclosporine pulmonary toxicity and CMV infection. The fact that this also occurs in patients with mitral valve disease who are not immunosuppressed is against the implication of these factors. Dr A. Haverich: Are you aware of any longitudinal studies on lung function in renal or hepatic transplant patients?
Dr 0. Al-Rawas: Yes there are few limited studies in renal and liver transplant patients. However, the pulmonary pathophysiology in these patients is completely dlifferent from that of heart transplant patients both before and after transplantation. In liver transplant, the pulmonary transfer factor is reduced before transplantation and does not change after transplantation. In renal transplant patients cyclosporine has been shown to have no effect on lung function including the pulmonary transfer factor. Dr A. Haverich: That is very important. So you leave us with impression that a better heart makes the lung worse.
Dr 0. Al-Rawaa: Well, it is not necessarily so. I think the reduction in pulmonary transfer factor is probably a marker of persistent pulmonary vascular dysfimction rather than an evidence of worsening lung function secondary to new insults to the lung such as opportunistic infections and drug toxicity after heart transplantation.
